Burden of HD Chorea
- Status: Completed
Project AWARE 2.0
- Status: Completed
KINECT-HD2
- Status: Completed
An Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington Disease.
Making HD Voices Heard
- Status: Completed
Making HD Voices Heard was the first study hosted on the myHDstory® platform. This observational study captured data to represent how HD patients experience their symptoms and how the disease affects their wellbeing.
PROOF-HD
- Status: Completed
A Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pridopidine in patients with early stage of Huntington disease.
KINECT-HD
- Status: Completed
A Phase 3, randomized, double-blind, placebo-controlled study to Evaluate the efficacy of valbenazine to reduce chorea associated with HD, evaluate the safety and tolerability of valbenazine in subjects with HD, and evaluate the ability of wearable movement sensors to detect changes in physical activity (optional activity).
Signal
- Status: Completed
A Phase II research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will assess the safety, tolerability, and effectiveness of VX15 (a novel monoclonal antibody).
HD Care Improvement Project
- Status: Completed
The Griffin Foundation established the Huntington’s Disease Care Improvement Project (HDCIP) with the Huntington Study Group (HSG) early in 2017 to help understand and improve the care experience for Huntington disease (HD) patients and families.
Legato-HD
- Status: Completed
A multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquininmod as treatment in patients with Huntington’s Disease.
The Pride-HD Study
- Status: Completed
Arc-HD
- Status: Completed
A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease for those currently taking tetrabenazine to treat chorea and “switch” to SD-809 ER.
Crest-EHD Study
- Status: Completed
Creatine Safety, Tolerability, and Efficacy in Huntington’s disease.
2Care
- Status: Completed
Coenzyme Q10 (CoQ) in Huntington’s Disease.
PREQUEL
- Status: Completed
A Multi-Center, Tolerability Study of Coenzyme Q10 (UbiquinonE) in PREmanifest Huntington’s disease.
Reach2HD
- Status: Completed
A Multi-Center, Phase II Safety and Tolerability Trial of PBT2 in Patients with Early to Mid-stage HD.
Hart
- Status: Completed
A Multi-Center, Study Comparing Three Doses Of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease.
Predict-HD
- Status: Completed
Observational Study of Neurobiological Predictors of Huntington’s Disease.